Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

Emerging Strategies in Multi-Cancer Early Detection

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Recent estimates show that only 14 percent of cancers are detected through routine screening, meaning the majority of patients are diagnosed after the onset of clinical symptoms. But multi-cancer early detection (MCED) tests offer the opportunity to potentially expand our ability to detect cancer through a single blood draw. Explore how MCED tests might help bridge the gaps that exist in today’s cancer screening paradigm and the recent studies on these tests with Drs. Tom Beer and Betsy O’Donnell. Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation, and Dr. O’Donnell is the Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute.

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Recent estimates show that only 14 percent of cancers are detected through routine screening, meaning the majority of patients are diagnosed after the onset of clinical symptoms. But multi-cancer early detection (MCED) tests offer the opportunity to potentially expand our ability to detect cancer through a single blood draw. Explore how MCED tests might help bridge the gaps that exist in today’s cancer screening paradigm and the recent studies on these tests with Drs. Tom Beer and Betsy O’Donnell. Dr. Beer is the Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation, and Dr. O’Donnell is the Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute.

Schedule7 Oct 2024